Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Foveal

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    104 result(s) found for: Foveal. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2005-001722-92 Sponsor Protocol Number: 1 Start Date*: 2005-10-12
    Sponsor Name:The Ludwig Boltzmann Institute for Retinology and Biomicroscopic Lasersurgery
    Full Title: Systemic Bevacizumab (Avastin®) Therapy for Exudative Neovascular Age-Related Macular Degeneration (BEAT-AMD-Study)
    Medical condition: Age related macular degeneration (AMD) patients with fibrovascular pigment epithelium detachment (PED), subfoveal choroidal neovascularisations (CNV) extending under the geometric center of the fov...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-002635-28 Sponsor Protocol Number: OFT-Campos01-12 Start Date*: 2013-04-19
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: ASSESSMENT OF THE EFFICACY OF SUBTENON NATURAL LEUCOCYTIC INTERFERON-α (IFNα) FOR THE TREATMENT OF DIABETIC MACULAR EDEMA (DME): A PILOT STUDY.
    Medical condition: DIABETIC MACULAR EDEMA (DME)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004853 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001385-16 Sponsor Protocol Number: 7 Start Date*: 2008-02-21
    Sponsor Name:Ludwig Boltzmann Institute for Retinology and Biomicroscopic Laser Surgery, Rudolf Foundation Clinic
    Full Title: Rheohemapheresis and Lutein Supplementation (xantophyll carotenoid) in the Non-Exsudative Form of Age-Related Macular Degeneration. (ReLux-AMD)
    Medical condition: Non-exsudative age-related macular degeneration
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003816-19 Sponsor Protocol Number: V4061 Start Date*: 2016-10-14
    Sponsor Name:ForSight VISION4, Inc
    Full Title: A Controlled Safety and Preliminary Efficacy Study of the V406 Port Delivery System in the Treatment of Choroidal Neovascularization Due toAge-Related Macular Degeneration
    Medical condition: Patients of either sex, 50 years of age or older, with a diagnosis of Choroidal Neovascularization CNV due to Age-Related Macular Degeneration AMD in the study eye
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: LV (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-007232-18 Sponsor Protocol Number: CRFB002AHU04T Start Date*: 2009-03-19
    Sponsor Name:University of Szeged, Medical and Pharmaceutical Center, Department of Ophthalmology [...]
    1. University of Szeged, Medical and Pharmaceutical Center, Department of Ophthalmology
    2. Semmelweis University Department of Ophthalmology
    3. Cholnoky F. County Hospital Veszprém Department of Ophthalmology
    Full Title: Comparison of the effect of intravitreal ranibizumab injections compared to macular grid-pattern laser therapy for the symptomatic treatment of diabetic macular edema (a randomized, controlled, pha...
    Medical condition: Diabetic Macular Edema
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003652-36 Sponsor Protocol Number: OZR-2011-17 Start Date*: 2012-11-30
    Sponsor Name:The Rotterdam Eye Hospital
    Full Title: The Most Effective Treatment Strategy for Diabetic Macular Edema.
    Medical condition: diabetic macular edema
    Disease: Version SOC Term Classification Code Term Level
    15.0 10015919 - Eye disorders 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-017540-13 Sponsor Protocol Number: Start Date*: 2010-07-27
    Sponsor Name:Clinical Trials and Research Governance
    Full Title: A Phase IV Open-Labelled Prospective Pilot Study of Intravitreal Macugen (pegaptanib) for Ischaemic Diabetic Macular Oedema (MIDME study)
    Medical condition: Ischaemic diabetic macular oedema.
    Disease: Version SOC Term Classification Code Term Level
    12 10057915 diabetic macular oedema SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2008-008259-41 Sponsor Protocol Number: OZR-2008-20 Start Date*: 2009-03-30
    Sponsor Name:Rotterdam Eye Hospital
    Full Title: Anti-VEGF (bevacizumab/ranibizumab) versus RPE-choroid graft in the treatment of 1) non-responders to 3 intravitreal anti-VEGF injections, or 2) patients with AMD and pigment epithelium rip, or 3) ...
    Medical condition: Age related macular degeneration and either of the following conditions: 1) not responding to 3 intravitreal anti-VEGF injections, or 2) pigment epithelium rip, or 3) massive haemorrhage.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2008-005789-30 Sponsor Protocol Number: IOBA-03-2008 Start Date*: 2009-04-22
    Sponsor Name:María Isabel López Gálvez-Instituto Universitario de Oftalmobiología Aplicada-Universidad Valladolid
    Full Title: Estudio de la eficacia y seguridad de inyecciones intravítreas de bevacizumab en el edema macular secundario a oclusiones venosas retinianas (EBOVER)
    Medical condition: Edema macular secundario a oclusiones venosas retinianas
    Disease: Version SOC Term Classification Code Term Level
    9.1 10030009 Occlusion retinal vein LLT
    9.1 10054467 Macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-000165-20 Sponsor Protocol Number: OZUROFT01/12 Start Date*: 2012-04-13
    Sponsor Name:Fundación para la Investigación biomédica del Hospital Universitario Ramón y Cajal. Madrid
    Full Title: SEQUENTIAL CLINICAL TRIAL TO EVALUATE THE EFFECTIVENESS OF INTRAVITREAL BEVACIZUMAB AS RESCUE TREATMENT OF RECURRENT MACULAR EDEMA SECONDARY TO RETINAL VEIN OCCLUSION TREATED WITH OZURDEX
    Medical condition: Macular edema secondary to retinal vein occlusion
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10038907 Retinal vein occlusion PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-006085-42 Sponsor Protocol Number: TG-MV-004 Start Date*: 2007-01-24
    Sponsor Name:ThromboGenics Ltd.
    Full Title: A Randomized, Sham-Injection Controlled, Double-Masked, Ascending-Dose, Dose-Range-Finding, Multicenter Trial of Microplasmin Intravitreal Injection for Non-Surgical PVD Induction for Treatment of ...
    Medical condition: Vitreomacular Traction Syndrome
    Disease: Version SOC Term Classification Code Term Level
    8.1 10051065 Vitreomacular traction syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-000975-21 Sponsor Protocol Number: RET-AFLI-2014-01 Start Date*: 2014-06-16
    Sponsor Name:Fundación Retinaplus +
    Full Title: A phase IV study to evaluate the effectiveness of aflibercept in naive patients with macular edema secondary to Central Retinal Vein Occlusion (CRVO) on an individualized Treat and Extend regimen. ...
    Medical condition: Macular edema secondary to central retinal vein occlusion.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000300-10 Sponsor Protocol Number: IDI-AFLI-2013-01 Start Date*: 2014-04-23
    Sponsor Name:Fundació Instituto de Investigación Biomédica de Bellvitge (Fundació IDIBELL)
    Full Title: Phase IV study to evaluate the efficacy of aflibercept in naive patients with retinal angiomatous proliferation (RAP) lesions on an individualized ?Treat and Extend? (TAE) regimen. AFLIRAP Study.
    Medical condition: Retinal angiomatous proliferation lesions (RAP)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-012509-20 Sponsor Protocol Number: MERLOT Start Date*: 2009-07-28
    Sponsor Name:King's College Hospital NHS Foundation Trust
    Full Title: A randomised controlled trial of epimacular brachytherapy versus ranibizumab monotherapy for the treatment of subfoveal choroidal neovascularisation associated with wet age-related macular degenera...
    Medical condition: Wet age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    12.0 10067791 Wet macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-000250-19 Sponsor Protocol Number: CADODIAME Start Date*: 2017-06-13
    Sponsor Name:Fundació Hospital Universitari Vall d'Hebron - Institut de Recersa (VHIR)
    Full Title: Effect of calcium dobesilate in early stages of diabetic retinopathy
    Medical condition: Diabetic retinopathy
    Disease: Version SOC Term Classification Code Term Level
    19.1 10015919 - Eye disorders 10012689 Diabetic retinopathy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-004917-10 Sponsor Protocol Number: TIGER Start Date*: 2023-06-29
    Sponsor Name:King's College London [...]
    1. King's College London
    2. King's College Hospital NHS Foundation Trust
    Full Title: Vitrectomy, subretinal Tissue plasminogen activator and Intravitreal Gas for submacular haemorrhage secondary to Exudative age-Related macular degeneration (TIGER): a phase 3, pan-European, two-gro...
    Medical condition: Submacular haemorrhage secondary to exudative age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10075718 Exudative age-related macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-010825-37 Sponsor Protocol Number: CRFB002DES01 Start Date*: 2009-06-29
    Sponsor Name:Novartis Farmaceutica S.A
    Full Title: Ensayo clínico de fase II, controlado, abierto, aleatorizado y multicéntrico, para comparar la eficacia y la seguridad de ranibizumab (inyección intravítrea) frente a fotocoagulación láser en pacie...
    Medical condition: Edema macular diabético
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057915 Diabetic macular oedema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-001970-41 Sponsor Protocol Number: 0504-19 Start Date*: 2022-03-18
    Sponsor Name:Intas Pharmaceuticals Ltd.
    Full Title: A Double Masked, Parallel Group, Randomized, Multicenter, Clinical Study to Compare Efficacy and Safety of Intas Ranibizumab with Lucentis® in Patients with Neovascular (Wet) Age-Related Macular De...
    Medical condition: Neovascular (Wet) Age-Related Macular Degeneration (AMD)
    Disease: Version SOC Term Classification Code Term Level
    27.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) PL (Completed) LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004783-35 Sponsor Protocol Number: OPH2005 Start Date*: 2018-07-10
    Sponsor Name:IVERIC bio
    Full Title: A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects with Autosomal Recessive Stargardt Disease
    Medical condition: Autosomal Recessive Stargardt Disease
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10062766 Stargardt's disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing) GB (GB - no longer in EU/EEA) HU (Completed) ES (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003643-30 Sponsor Protocol Number: VGFTe-HD-DME-1934 Start Date*: 2020-06-03
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Masked, Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Patients with Diabetic Macular Edema
    Medical condition: Diabetic Macular Edema
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) HU (Completed) CZ (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 11 23:42:58 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA